美银证券：重申信达生物(01810)“买入”评级上调目标价至61.1港元_老虎社区_美港股上老虎

美银证券：重申信达生物(01810)“买入”评级上调目标价至61.1港元

金融界2025-04-25

智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

一次韭好
·2025-04-26
代码都打错了
回复
1
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2530597182?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-25 15:56","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530597182","market":"hk","top_or_hot":-1,"title":"美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元","media":"金融界","content":"<div>\n<p>智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-25 15:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01810","symbol_name":"小米集团-W","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b","article_id":"2530597182","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530597182","pubTimestamp":1745567816,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键资产的长期销售预测。本文源自：智通财经网","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01810":"小米集团-W","01801":"信达生物"},"translate_title":"Bank of America Securities: Reiterate Innovent Biologics (01810) \"buy\" rating and raise target price to HK $61.1","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01810":1,"01801":1},"content_text":"智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键资产的长期销售预测。本文源自：智通财经网","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"rating","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":428359276040312,"gmtCreate":1745610509614,"gmtModify":1745619004521,"author":{"id":"3494800443838167","authorId":"3494800443838167","name":"一次韭好","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3494800443838167","idStr":"3494800443838167"},"htmlText":"代码都打错了","listText":"代码都打错了","text":"代码都打错了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/428359276040312","repostId":2530597182,"repostType":2,"repost":{"id":"2530597182","kind":"news","pubTimestamp":1745567816,"share":"https://www.laohu8.com/m/news/2530597182?lang=zh_CN&edition=full","pubTime":"2025-04-25 15:56","market":"hk","language":"zh","title":"美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530597182","media":"金融界","summary":"智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键资产的长期销售预测。本文源自：智通财经网","content":"<html><body><article><p>智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调<a href=\"https://laohu8.com/S/01801\">信达生物</a>(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。</p><p>信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键<span>资产</span>的长期销售预测。</p><p>本文源自：智通财经网</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-25 15:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01810":"小米集团-W","01801":"信达生物"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2530597182","content_text":"智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键资产的长期销售预测。本文源自：智通财经网","news_type":1,"symbols_score_info":{"01810":1,"01801":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}